AAAAAA
Results:
1-7
|
Results: 7
Authors:
Smyth, J
Boneterre, ME
Schellens, J
Calvert, H
Greim, G
Wanders, J
Hanauske, A
Citation: J. Smyth et al., Activity of the dolastatin analogue, LU103793, in malignant melanoma, ANN ONCOL, 12(4), 2001, pp. 509-511
Authors:
Maxwell-Armstrong, CA
Durrant, LG
Buckley, TJD
Scholefield, JH
Robins, RA
Fielding, K
Monson, JRT
Guillou, P
Calvert, H
Carmichael, J
Hardcastle, JD
Citation: Ca. Maxwell-armstrong et al., Randomized double-blind phase II survival study comparing immunization with the anti idiotypic monoclonal antibody 105AD7 against placebo in advancedcolorectal cancer, BR J CANC, 84(11), 2001, pp. 1443-1446
Authors:
Friedman, HS
Kerby, T
Calvert, H
Citation: Hs. Friedman et al., Temozolomide and treatment of malignant glioma, CLIN CANC R, 6(7), 2000, pp. 2585-2597
Authors:
Pavlidis, N
Aamdal, S
Awada, A
Calvert, H
Fumoleau, P
Sorio, R
Punt, C
Verweij, J
van Oosterom, A
Morant, R
Wanders, J
Hanauske, AR
Citation: N. Pavlidis et al., Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG), CANC CHEMOT, 46(2), 2000, pp. 167-171
Authors:
Hughes, A
Calvert, H
Citation: A. Hughes et H. Calvert, An update on thymidylate synthase inhibitors, ANN ONCOL, 10(10), 1999, pp. 1137-1139
Authors:
Calvert, H
Citation: H. Calvert, An overview of folate metabolism: Features relevant to the action and toxicities of antifolate anticancer agents, SEMIN ONCOL, 26(2), 1999, pp. 3-10
Authors:
Calvert, H
Citation: H. Calvert, MTA: Summary and conclusions, SEMIN ONCOL, 26(2), 1999, pp. 105-108
Risultati:
1-7
|